Advantage Alpha Capital Partners LP Sells 17,761 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Advantage Alpha Capital Partners LP trimmed its stake in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 66.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,873 shares of the company’s stock after selling 17,761 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Gyre Therapeutics were worth $107,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC acquired a new position in shares of Gyre Therapeutics during the third quarter worth $47,000. Barclays PLC increased its holdings in Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. Bank of New York Mellon Corp raised its position in Gyre Therapeutics by 11.1% in the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock valued at $168,000 after purchasing an additional 1,389 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Gyre Therapeutics during the fourth quarter valued at about $1,225,000. Finally, State Street Corp grew its holdings in shares of Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares during the last quarter. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Stock Performance

Shares of NASDAQ:GYRE opened at $9.21 on Tuesday. Gyre Therapeutics, Inc. has a 52 week low of $8.26 and a 52 week high of $19.00. The firm has a market cap of $862.17 million, a PE ratio of 184.20 and a beta of 1.93. The firm’s fifty day moving average is $11.29 and its 200-day moving average is $12.18.

Gyre Therapeutics (NASDAQ:GYRE) last announced its earnings results on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.03). The company had revenue of $27.87 million for the quarter, compared to analyst estimates of $23.50 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.

Insider Buying and Selling

In related news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 36,054 shares of company stock valued at $407,317 over the last ninety days. 19.52% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, Noble Financial initiated coverage on shares of Gyre Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating for the company.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.